Anne Sophie Kubasch

MD, Clinician Scientist #Hematology | #CellularTherapy | #Hemostaseology Unit, University Hospital Leipzig @UKL_Leipzig |

[Anne Sophie Kubasch @ASKubasch]

Yesterday, we presented the results of the LUCAS and CANFIRE trials at #ASH 2024 in San Diego (Poster ID: 199032). Our studies investigated IRAK4 and IL-1β blockade in lower-risk #MDS to address #inflammation-driven ineffective hematopoiesis.
@ASH_hematology

[Anne Sophie Kubasch @ASKubasch]

@DavidSteensma @BloodClotDoc @mpdrc @ninashah33 Thanks for sharing 🙏

[VJHemOnc @VJHemOnc]

Do you want to hear about the latest breakthroughs in digital medicine & artificial intelligence in cancer care?

Register here for the upcoming Shaping the Future of Medicine symposium taking place on 24 & 25 Sept:
👉 https://t.co/voXjqqFxK6 👈

#AI #HemOnc #LLMs @ShapFutureMed

[Anne Sophie Kubasch @ASKubasch]

Don‘t miss our @ShapFutureMed symposium in Leipzig on Sept 24-25,2024. @Google’s Vivek Natarajan will be there in person and share his invaluable insights on the transformative role of artificial intelligence in healthcare. https://t.co/NieI4wFz1G
#LLMs #STFOM2024 @GoogleHealth

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

What an amazing day full of great talks & great discussions at the #iwMDS24 this is how we move the #MDSsm field forward

[VJHemOnc @VJHemOnc]

#iwMDS24 | Join @ASKubasch of @UKL_Leipzig discusses new digital tools in hematology

@VJHemOnc #iwMDS24 #MDSsm #MDS

[AML Hub @AML_Hub]

CONGRESS | #EHA2024
Anne Sophie Kubasch @ASKubasch @UKL_Leipzig presented long-term data showing that MRD-guided pre-emptive treatment with Aza delayed relapse in patients with MRD-positivity in the phase II open-label RELAZA2 study in patients with MDS or AML.
▪️ After median follow-up of 22.5 months (n=95), 63% patients were relapse-free after 6 months (primary endpoint)
▪️ Rate of major MRD response (reachieving MRD negativity)=65%; minor MRD response (absence of major response + no hematological relapse)=35%
▪️ Favourable ELN risk, time from last treatment, and lower MRD level associated with response to Aza
▪️ No new safety signals identified
#AMLsm #mdssm #leusm #hematology #MedicalCongress

[Anne Sophie Kubasch @ASKubasch]

Enjoyed reconnecting with these two fantastic colleagues, @sanamloghavi and @KatjaSockel, during the #EHA2024 meeting in Madrid this week 🇪🇸 @EHA_Hematology

[Anne Sophie Kubasch @ASKubasch]

At the @EHA_Hematology Association meeting in #Madrid, we had the privilege of presenting the long-term follow-up results of our #RELAZA2 study, which focuses on the efficacy of #azacitidine in treating measurable residual disease (#MRD) in #MDS and #AML! #EHA2024

[AML Hub @AML_Hub]

CONGRESS | #EHA2024
Anne Sophie Kubasch @ASKubasch @UKL_Leipzig presents long-term follow-up of the phase II open-label RELAZA2 study of Aza in the treatment of MRD in MDS and AML.
MRD-guided pre-emptive treatment with Aza was found to be efficacious in preventing/delaying relapse in patients with MRD-positivity:
▪️ 63% patients were relapse-free after 6 months
▪️ Rate of major MRD response (reachieving MRD negativity)=65%; minor MRD response (absence of major response and no hematological relapse)=35%,
However, additional pre-emptive strategies are needed.
#AMLsm #mdssm #leusm #hematology #MedicalCongress

[Anne Sophie Kubasch @ASKubasch]

Just released! Please check out our @ShapFutureMed #FeaturingCancer preliminary program! Join us and register here: https://t.co/MFK11fXYFM

[Anne Sophie Kubasch @ASKubasch]

The preliminary program for our @ShapFutureMed #NextGenCancerInnovater Symposium is now online! Come and join us and register here: https://t.co/MFK11fYwvk

[Anne Sophie Kubasch @ASKubasch]

The countdown begins, register now and join us! #STFOM

[Shaping the Future of Medicine Leipzig @ShapFutureMed]

Registration for #STFOM2024 starting September 24 until 25, 2024 is now open. Stay tuned for regular program updates in the coming weeks! Please register here: https://t.co/O5bnbCuny4

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Thrilled to see our i4MDS position paper out in @Hemasphere_EHA today. This work was led by @KordastiL and provides a framework for immune monitoring in patients with #MDSsm and related conditions. The aim of i4MDS is to enhance MDS stratification, identify predictive markers of response, and accelerate the development of novel therapies via identifying and incorporating immunological data into the diagnosis and management of #MDSsm #CHIP #CCUS #hemepath

https://t.co/YpnJZvsfKF

[Anne Sophie Kubasch @ASKubasch]

Yesterday, #Chemnitz hosted the esteemed #Saxon #AI #Congress, which featured a robust discussion on #Saxony's #AI #strategy and the release of the latest study assessing #Saxony's #AI landscape:
https://t.co/L4yveEW2OW
@SachsenDe @MPKretschmer

[Anne Sophie Kubasch @ASKubasch]

@KensingtonRoyal Prayers for you 🙏🙏🙏

[Anne Sophie Kubasch @ASKubasch]

During the Leipzig Hematology Symposium #LHS, we discussed how to illuminate the #patient pathway towards more #personalized, efficient, and accessible #cancer #care through the integration of #digital #technologies.

[Deutsches Ärzteblatt @Dt_Aerzteblatt]

Verbesserter Zugang zu innovativen Therapien durch Netzwerke: Berlin – Vom Zugang zu innovativen Therapien in der klinischen Praxis profitieren medizinisch nicht nur Patienten, sondern wirtschaftlich auch… https://t.co/2MEdO43pVE #SaxoCell #Forschung #Therapien #Innovation

[SaxoCell @SaxoCell]

Was braucht es, um #ATMPs in #Sachsen zu entwickeln? Wie kann der Zulassungsprozess beschleunigt und Kosten gesenkt werden? Diese und weitere Fragen diskutierten wir mit Vertretern aus Politik, Medizin, Gesundheitswesen und Industrie bei #SaxoCell meets #Politics in Berlin!

[Anne Sophie Kubasch @ASKubasch]

This week I had the opportunity to meet with Prof Matteo Della Porta and his team at the #AI Center, @HUNIMED Research Hospital. The synergy between #technology, #hematology and the groups commitment to #innovation was a really enriching experience for future #collaborations.